TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer

Image 1-TUKYSA (tucatinib)
TUKYSATM (tucatinib) in combination with trastuzumab and capecitabine is indicated for the treatment of HER2-positive breast cancer. Photo: Business Wire.